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Currently the world faces epidemic of several closely related conditions: obesity, metabolic syndrome and type 2
diabetes (T2DM). The lipid profile of these patients and those with metabolic syndrome is characterized by the
concurrent presence of qualitative as well as quantitative lipoprotein abnormalities: low levels of HDL, increased
triglycerides, and prevalence of LDL particles that are smaller and denser than normal. This lipid phenotype has
been defined as atherogenic dyslipidemia. Overwhelming evidences demonstrate that all components of the
atherogenic dyslipidemia are important risk-factors for cardiovascular diseases. Optimal reduction of cardiovascular
risk through comprehensive management of atherogenic dyslipidemias basically depends of the presence of
efficacious lipid-modulating agents (beyond statin-based reduction of LDL-C). The most important class of
medications which can be effectively used nowadays to combat atherogenic dyslipidemias is the fibrates. From a
clinical point of view, in all available 5 randomized control trials beneficial effects of major fibrates (gemfibrozil,
fenofibrate, bezafibrate) were clearly demonstrated and were highly significant in patients with atherogenic
dyslipidemia. In these circumstances, the main determinant of the overall results of the trial is mainly dependent of
the number of the included appropriate patients with atherogenic dyslipidemia. In a meta-analysis of dyslipidemic
subgroups totaling 4726 patients a significant 35% relative risk reduction in cardiovascular events was observed
compared with a non significant 6% reduction in those without dyslipidemia. However, different fibrates may have
a somewhat different spectrum of effects. Currently only fenofibrate was investigated and proved to be effective in
reducing microvascular complications of diabetes. Bezafibrate reduced the severity of intermittent claudication.
Cardinal differences between bezafibrate and other fibrates are related to the effects on glucose metabolism and
insulin resistance. Bezafibrate is the only clinically available pan - (alpha, beta, gamma) PPAR balanced activator.
Bezafibrate decreases blood glucose level, HbA1C, insulin resistance and reduces the incidence of T2DM compared
to placebo or other fibrates. Among major fibrates, bezafibrate appears to have the strongest and fenofibrate the
weakest effect on HDL-C. Current therapeutic use of statins as monotherapy is still leaving many patients with
atherogenic dyslipidemia at high risk for coronary events because even intensive statin therapy does not eliminate
the residual cardiovascular risk associated with low HDL and/or high triglycerides. As compared with statin
monotherapy (effective mainly on LDL-C levels and plaque stabilization), the association of a statin with a fibrate
will also have a major impact on triglycerides, HDL and LDL particle size. Moreover, in the specific case of
bezafibrate one could expect neutralizing of the adverse pro-diabetic effect of statins. Though muscle pain and
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myositis is an issue in statin/fibrate treatment, adverse interaction appears to occur to a significantly greater extent
when gemfibrozil is administered. However, bezafibrate and fenofibrate seems to be safer and better tolerated.
Combined fibrate/statin therapy is more effective in achieving a comprehensive lipid control and may lead to
additional cardiovascular risk reduction, as could be suggested for fenofibrate following ACCORD Lipid study
subgroup analysis and for bezafibrate on the basis of one small randomized study and multiple observational data.
Therefore, in appropriate patients with atherogenic dyslipidemia fibrates- either as monotherapy or combined with
statins – are consistently associated with reduced risk of cardiovascular events. Fibrates currently constitute an
indispensable part of the modern anti-dyslipidemic arsenal for patients with atherogenic dyslipidemia.
Keywords: Atherogenic dyslipidemia, Bezafibrate, Combined fibrate/statin therapy, Fenofibrate, Metabolic
syndrome, Residual cardiovascular risk, Type 2 diabetesFigure 1 Atherogenic Dyslipidemia triad: the lipid profile which
is typical for patients with type 2 diabetes and the metabolic
syndrome is characterized by the low HDL-C, increased
triglycerides and prevalence of small, dense LDL particles.Atherogenic dyslipidemia
Currently the world faces epidemic of closely related
conditions: obesity, metabolic syndrome and type 2 dia-
betes (T2DM) [1-6]. A strong correlation between T2DM
and cardiovascular diseases is well established [7-9]. Also
for the metabolic syndrome (MetS) the best available evi-
dence from randomized control trials (RCT) and large
meta-analyses systematically had shown increased risk of
cardiovascular events [10-14]. The recent and largest
meta-analysis [12] included near one million patients
(total n = 951,083). The investigators concluded that the
MetS is associated with a 2-fold increase in cardiovascular
outcomes and a 1.5-fold increase in all-cause mortality
rates.
The lipid profile of patients with T2DM and MetS is
characterized by the concurrent presence of qualitative
as well as quantitative lipoprotein abnormalities: low
levels of high density lipoprotein cholesterol (HDL-C)
(<50 mg/dl in women, < 40 mg/dl in men), increased tri-
glycerides (TG >150 mg/dl), and prevalence of low dens-
ity lipoprotein (LDL) particles that are smaller and
denser than normal (Figure 1). This lipid phenotype has
been defined as atherogenic dyslipidemia [15-20]. Inter-
estingly, elevated LDL cholesterol (LDL-C) level is not
typical of T2DM nor MetS. Overwhelming evidences
demonstrate that all components of the atherogenic dys-
lipidemia are important risk-factors for cardiovascular
diseases [21-25].
Particularly, a strong association exists between ele-
vated triglycerides and cardiovascular disease. However,
the extent to which triglycerides directly promote dis-
ease or represent a biomarker of risk has been debated
for decades. The largest and most comprehensive recent
meta-analysis included 29 prospective studies and
262,525 participants, proving a strong and highly signifi-
cant association between triglycerides and coronary risk.
Adjustment for HDL-C attenuated the magnitude but
did not abolish the significant association between trigly-
cerides and coronary risk [26]. The triglyceride -rich en-
vironment has been shown to be strongly associatedwith an atherogenic lipoprotein phenotype or atherogenic
dyslipidemia [22]. In the United States, the National
Health and Nutrition Examination Survey (NHANES) has
monitored biomarkers of cardiovascular risk for 3 decades.
Accordingly, increases in fasting serum triglyceride levels
were observed between surveys conducted in 1976–1980
and 1999–2002 [27]. Also, nonfasting triglyceride strongly
correlated with coronary risk [28,29]. There is a broad
agreement that reverse cholesterol transport, the process
of transporting excess cholesterol from the arterial wall’s
foam macrophages to the liver, bile, and feces is one of
HDL’s important anti-atherogenic properties. Circulating
HDL particles are greatly heterogeneous with a very com-
plex metabolic profile. HDL-C measures the cholesterol
content of nascent HDL, HDL2, and HDL3 particles and
is, therefore, a crude marker of reverse cholesterol trans-
port, whereas non-HDL-cholesterol is a valid marker of
coronary risk [30-34].
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comprehensive management of atherogenic dyslipide-
mias basically depends of the presence of efficacious
lipid-modulating agents (beyond statin-based reduction
of LDL-C). However, most of these agents are currently
under serious concerns: niacin after negative AIM HIGH
study [35] and before HPS-2 THRIVE trial results, and
cholesteryl ester transfer protein (CETP) -inhibitors and
glitazars are still in controversial developments and not
available for clinical use. Omega-3 polyunsaturated fatty
acids supplementation seems to not really influence
major cardiovascular outcomes [36]. Therefore, the single
class of medications which can be at the moment effectively
used to combat atherogenic dyslipidemia beyond statins is
only fibric acid derivatives - fibrates.
The role of fibrates in the management of
atherogenic dyslipidemia
Fibrates are used in clinical practice for about half century
due to their ability to substantially decrease triglyceride
levels and increase HDL. All fibrates are peroxisome
proliferators-activated receptors (PPARs) α agonists. Fibrates
enhance the oxidation of fatty acids (FA) in liver and muscle
and reduce the rate of hepatic lipogenesis, thereby reducing
secretion of very-low-density lipoprotein (VLDL) triglycer-
ides. The increased uptake of triglyceride-derived fatty acids
in muscle cells results from an increase in lipoprotein lipase
(LPL) activity in adjacent capillaries and a decrease in the
apolipoprotein CIII (Apo CIII) concentration mediated tran-
scriptionally by PPAR alpha. The decrease in apolipoprotein
CIII reduces the inhibition of LPL activity. The enhanced ca-
tabolism of VLDL generates surface remnants, which are
transferred to HDL. HDL concentrations are further aug-
mented by an increase in PPARα - mediated transcrip-
tion of apolipoprotein AI (Apo AI) and apolipoprotein
AII (Apo AII). Ultimately, the rate of HDL-mediatedTable 1 Results from the all outcomes trials with the major fi
Study Primary analysis:
RRR (p value)(Treatment)
HHS [32,43] −34% (<0.02)
(Gemfibrozil)
VA-HIT [44] −22% (0.006)
(Gemfibrozil)
BIP [42] −9.4% (0.24)
(Bezafibrate)
FIELD [41,45] −11% (0.16)
(Fenofibrate)
ACCORD Lipid [39] −8% (0.32)
(Fenofibrate)
RRR – relative risk reduction.reverse cholesterol transport may increase. Fibrates ac-
tivate PPARα, which binds to a PPARα response elem-
ent in conjunction with the retinoid X receptor. Other
effects of fibrates include an increase in the size of
LDL particles, increased removal of LDL, and a reduc-
tion in the levels of plasminogen activator inhibitor
type I [37,38].
From a clinical point of view, in all available 5 rando-
mized control trials (Table 1) the beneficial effects of
major fibrates (gemfibrozil, fenofibrate, bezafibrate) were
clearly demonstrated and were highly significant in
patients with atherogenic dyslipidemia [39-45]. For ex-
ample, fenofibrate in the FIELD study: no significance in
“general population”, already significant 14% risk reduc-
tion in low HDL subgroup, 23% significant risk reduc-
tion in high triglycerides subgroup and 27% significant
risk reduction in patients with atherogenic dyslipidemia
[41]. In the earliest and the most successful Helsinki
Heart Study with gemfibrozil, near all benefits were
derived from the patients with atherogenic dyslipidemia
without any impressive effects in other subgroups [43].
The same is true for bezafibrate in the BIP trial [42], for
fenofibrate in the ACCORD-Lipid trial [39] and for gem-
fibrozil in the VA-HIT trial [44]. We can see amazing
similarity among all fibrates trials. In these circum-
stances, the key determinant of the overall results of the
trial is dependent mainly on the number of the included
appropriate patients with atherogenic dyslipidemia. So, in
the ACCORD-Lipid trial there were only 17% appropriate
patients with atherogenic dyslipidemia (941 of 5489)! In
these patients 31% risk reductions was achieved (hazard
ratio = 0.69, 95% confidence interval 0.49 - 0.97, p = 0.03
for within subgroup analysis, p for interaction = 0.057).
However, 83% of patients in this trial were inappropriate
for a fibrate treatment. Among them, the event rate was
10.1% in both treatment groups. Thus, overall results ofbrates (gemfibrozil, bezafibrate, fenofibrate)
Subgroup criteria Subgroup analysis:
RRR (p value)
TG >200 mg/dL −71% (0.005)
LDL-C/HDL-C >5.0
Diabetes −34% (0.004)
TG >200 mg/dL, −42% (0.02)
HDL-C < 35 mg/dL,
TG ≥200 mg/dL −27% (0.005)
HDL-C <40 mg/dL for men,
<50 mg/dL for women
TG ≥204 mg/dL −31% (0.03)
HDL-C ≤34 mg/dL
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this inappropriate patients selection lead to fail of the
study.
In a recent meta-analysis of five dyslipidemic subgroups
totaling 4726 patients, a 35% relative risk reduction in car-
diovascular events was observed compared with a non sig-
nificant 6% reduction in those without dyslipidemia [46].
Meta-analysis performed in a so called “general popula-
tion” [47] reflecting a blend of effects in patients with and
without atherogenic dyslipidemia - a “mean diluted” effect
of fibrate therapy was reduced, producing only 13% RR re-
duction for coronary events (p < 0.0001). Figure 2 illus-
trates a dilution effect in epidemiology: strong significant
cardiovascular risk reduction in patients with atherogenic
dyslipidemia, non significant effect in those without dysli-
pidemia and blended modest effect in the mixed “general
population”.
Therefore, in patients with atherogenic dyslipidemia
(high triglycerides and low HDL-C), fibrates - either as
monotherapy or combined with statins - are consistently
associated with reduced risk of cardiovascular events. In
patients without dyslipidemia this favorable effect - as
expected - is absent.
Fibrates: different spectrum of effects
However, different fibrates may have a somewhat dis-
similar spectrum of effects. Currently only fenofibrate
[39,41] was investigated in deep and proved to beFigure 2 Fibrates trials as an example of a dilution effect in epidemio
with atherogenic dyslipidemia [46], non significant effect in those wit
“general population” [47].effective in reducing microvascular complications of dia-
betes (in terms of diabetic retinopathy, progression of
microalbuminuria and risk of limb amputations). How-
ever, there is no reason to suggest that other fibrates
cannot do the same. The strongest hints for this were
obtained in the large LEADER study when bezafibrate
significantly reduced the severity of intermittent claudi-
cation for up to three years [48]. In addition, bezafibrate
effectively reduced microvascular complications in a ex-
perimental study [49]. Also in the old RCTs, clofibrate
was partially effective in the treatment of diabetic retin-
opathy due to an increased rate of absorption of hard
exudates [50,51].
The underlying mechanisms of these effects are not
fully elucidated. The reductions in the risk of T2DM-
related retinopathy and risk of amputation with fenofi-
brate were apparently independent of effects on lipid
parameters. The leading hypothesis included activation
of PPARα which can modulate angiogenesis through a
mechanism dependent on vascular endothelial growth
factor [52]. Actions arising via PPARα activation are
likely to be shared between all fibric acid derivatives
[52]. Alternatively, influence on endothelial function, anti-
inflammatory and anti-apoptotic effects and decreased cir-
culating levels of fibrinogen could be involved [52,53].
Cardinal differences between bezafibrate and other
fibrates are related to effects on glucose metabolism and
insulin resistance. Bezafibrate, in contrast to other fibrateslogy: strong significant cardiovascular risk reduction in patients
hout dyslipidemia [46] and a blended modest effect in the mixed
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[54,55]. Bezafibrate leads to long-term stabilization of in-
sulin sensitivity and pancreatic beta-cell function, reduced
blood glucose level and HbA1C [56-59]. In addition, beza-
fibrate significantly increased serum adiponectin level
[60]. Multiple studies have shown that bezafibrate
reduced the incidence of T2DM by 30-40% comparedFigure 3 A. Residual risk in people with diabetes and atherogenic dys
[66-74]. Red column represents the coronary risk in the people with diabe
placebo (blue column), and the patients without diabetes and atherogenic
demonstrate the additional coronary risk of the diabetic patients with athe
diabetes and atherogenic dyslipidemia: effect of intenesive statin therapy. T
based on the meta-analysis (it is presented by the white box) [80]. Residuato placebo or other fibrates during a long-term follow-
up period [61-63].
In patients with MetS, bezafibrate treatment was asso-
ciated with significant 29% reduced risk of any MI and
33% reduced risk of non-fatal MI. The early decrease in
MI incidence was reflected later in a tendency of
reduced cardiac mortality. Of note, among patients withlipidemia: effect of standard-dose statin therapy, pooled data
tes and atherogenic dyslipidemia treated by statins as compared to
dyslipidemia treated by statins (green column). The yellow arrows
rogenic dyslipidemia treated by statins. B. Residual risk in people with
he hypothetical extra benefit obtained by intensive statin therapy
l risk is still remained considerable
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a marked 56% reduction in cardiac mortality on bezafi-
brate was observed [64]. Of course, caution should be
used in interpreting these findings, which were identified
in a post-hoc analysis.
What is the place of fibrates in the statins world?
Until now, there were no direct “head to head” statin vs.
fibrate comparisons at all. Only recently intermediate-
size (274 patients) RCT have demonstrated that bezafi-
brate was significantly better than pravastatin (a rela-
tively weak statin) in reduction of cardiovascular events
[65]. Anyway, even intensive statin therapy does not
eliminate the cardiovascular risk associated with low
HDL or/and high triglycerides (atherogenic dyslipidemia)!
Current therapeutic use of statins as monotherapy is still
leaving many patients with combined dyslipidemia
(which included atherogenic dyslipidemia) at high re-
sidual risk for coronary events [38,66-74]. Figure 3A is a
graphic representation of the definition of residual car-
diovascular risk in patients treated by conventional sta-
tin therapy. The significant residual cardiovascular risk
is still present and is not affected by standard LDL -
lowering therapy.
The next step in the risk reduction was the concept of
“intensive” high dose statin therapy. Direct testing of
varying degrees (intensive vs. conventional) of LDL-C
lowering by using of active comparators (statin vs. statin)
has been tested in 5 large outcomes trials [75-79]: PROVE
IT--TIMI 22, A to Z, TNT, IDEAL and SEARCH. Out of
the 5 trials which investigated intensive vs. standard statin
regime, we have 2 “positive” with strong reservations:
PROVE IT-TIMI 22 (it was based on very strange
study design) and TNT (total death moved in a wrongFigure 4 Effect of different fibrates on HDL-C level (vs. placebo), HDL
significantly higher [32,39,41-45,48].direction) - and 3 “negative”: A to Z, IDEAL and
SEARCH. Anyway, pooled data were in favour of the inten-
sive statin therapy [80]. Figure 3B illustrates the hypothet-
ical extra benefit obtained by intensive statin therapy based
on the meta-analysis (represented by the white box). Re-
sidual risk is still remained considerable. Significant in-
crease in side effects during intensive therapy was observed
(elevations of liver enzymes, muscle aches, cognitive decline
and the development of diabetes mellitus) [38,80-83].
The risk associated with high triglycerides and low
HDL may be eliminated by fibrate. Among major
fibrates, bezafibrate appears to have the strongest [42,48]
and fenofibrate the weakest [39,45] effect on HDL-C
(Figure 4). As compared with statin monotherapy (ef-
fective mainly on LDL-C levels and plaque stabilization),
the association of a statin with a fibrate will also have a
major impact on triglycerides, HDL and LDL particle
size. Moreover, in the case of bezafibrate one could ex-
pect neutralizing of the adverse pro-diabetic effect of
statins. Though muscle pain and myositis is an issue in
statin/fibrate treatment, adverse interaction appears to
occur to a significantly greater extent when gemfibrozil
is administered. However, bezafibrate and fenofibrate
seem to be safer and better tolerated [84-93].
Particularly, plasma concentration of statins are mark-
edly increased by gemfibrozil but not by fenofibrate or
bezafibrate [89,90,93]. So, gemfibrozil, which is a good
“evidence-based” fibrate for monotherapy, apears to be a
problematic in the “statins world”. Unfortunately, safety
concerns about gemfibrozil may lead to exaggerate pre-
cautions regarding fibrate administration and therefore
diminish the use of these useful agents.
In a fibrate/statin combined therapy, the statin should
probably be taken at the evening and the fibrate in the-C elevations vs. baseline during a treatment usually were
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Anyway, although in clinical trials the rate of adverse
events on combination was not significantly greater
compared with monotherapy, clinical and laboratory
monitoring of patients who receive combined treatment
could be prudent.
Currently there are a few hard outcome evidences
regarding a combination statin/fibrate. In ACCORD
Lipid study fenofibrate leads to cardiovascular risk re-
duction in pre-specified subgroup of patients with
atherogenic dyslipidemia [39]. In the observational study
of the 150 patients, the combination of bezafibrate and
simvastatin was more effective than monotherapy
in reduction of cardiovascular events [92]. In the small
randomized controlled trial bezafibrate on top of
statin-based treatment was a safe and significantly
reduced major adverse cardiovascular events (MACE) in
patients with acute ST elevation MI [94]. The authors
particularly emphasized in this study ability of bezafi-
brate significantly reduced fibrinogen levels.
Recently, new data regarding statin/fibrate combin-
ation were published using the high quality comprehen-
sive nationwide ACSIS registry [95]. There were 8545
patients treated with statin alone and 437 patients
treated with a statin/fibrate combination (mainly
bezafibrate). Development of 30-day MACE (primary
end-point) was recorded in 6.0% patients from the statin
monotherapy group vs. 3.2% from the combination
group, (p = 0.01). 30-day re-hospitalization rate was also
significantly lower in the combination group. Kaplan-
Meier analysis of total mortality during one year was close
to significance in favor of the combination (p = 0.066).
Multivariate analysis identified the fibrate/statin combin-
ation as an independent predictor of 46% reduced risk of
MACE in overall population (p = 0.03). In the subgroup
interaction analysis the most impressive results were
found in the subgroup with diabetes and atherogenic dys-
lipidemia. As one could expect, in patients without dysli-
pidemia this effect was absent. It should be emphasized
that even though these “real world” observation data can-
not replace RCT, the consistency of the results supports
their credibility.
Conclusions
Even intensive statin therapy does not eliminate the
residual cardiovascular risk associated with atherogenic
dyslipidemia (low HDL and high triglycerides). Meta-
analyses of randomized control trials clearly demon-
strated that the main fibrates significantly reduce this
risk. Combined fibrate/statin therapy is more effective in
achieving a comprehensive lipid control and may lead to
additional cardiovascular risk reduction, as could be sug-
gested for fenofibrate following ACCORD Lipid study
subgroup analysis and for bezafibrate on the bais on onesmall randomized study and multiple observational data.
Therefore, in appropriate patients with atherogenic dys-
lipidemia fibrates- either as monotherapy or combined
with statins – are consistently associated with reduced
risk of cardiovascular events. Fibrates currently are an
indispensable part of the modern anti-dyslipidemic ar-
senal for patients with atherogenic dyslipidemia.
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